ADHD treatment co Alcobra raises $26 million on Nasdaq

– The company plans a second Phase III trial in the US for ADHD, drawing lessons from the previous Phase III trial.   Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD), which is developing a drug for More...

Alcobra Raises $33 Million In Secondary Nasdaq Offering

– The ADHD treatment developer raised $27 million in its IPO in May. –     Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD) raised a gross $33 million in its secondary offering on Thursday. More...

Mazor Robotics files to raise $46 million in American Depository Shares on Nasdaq

– CEO Ori Hadomi: The proceeds from the offering would be used to expand the company’s sales and marketing network in the US. – CEO Ori Hadomi – / By Tali Tsipori / Mazor Robotics Ltd. More...

Enzymotec publishes Nasdaq IPO prospectus

– Enzymotec, which has developed a proprietary method for processing fatty acids, is seeking to raise $75 million. – – / By Gali Weinreb /  Nutritional supplements company Enzymotec More...